Abstract
Background
In uncommon tremor disorders, clinical efficacy and optimal anatomical targets for deep brain stimulation (DBS) remain inadequately studied and insufficiently quantified.
Methods
We performed a systematic review of PubMed.gov and ClinicalTrials.gov. Relevant articles were identified using the following keywords: “tremor”, “Holmes tremor”, “orthostatic tremor”, “multiple sclerosis”, “multiple sclerosis tremor”, “neuropathy”, “neuropathic tremor”, “fragile X-associated tremor/ataxia syndrome”, and “fragile X.”
Results
We identified a total of 263 cases treated with DBS for uncommon tremor disorders. Of these, 44 had Holmes tremor (HT), 18 orthostatic tremor (OT), 177 multiple sclerosis (MS)-associated tremor, 14 neuropathy-associated tremor, and 10 fragile X-associated tremor/ataxia syndrome (FXTAS). DBS resulted in favorable, albeit partial, clinical improvements in HT cases receiving Vim-DBS alone or in combination with additional targets. A sustained improvement was reported in OT cases treated with bilateral Vim-DBS, while the two cases treated with unilateral Vim-DBS demonstrated only a transient effect. MS-associated tremor responded to dual-target Vim-/VO-DBS, but the inability to account for the progression of MS-associated disability impeded the assessment of its long-term clinical efficacy. Neuropathy-associated tremor substantially improved with Vim-DBS. In FXTAS patients, while Vim-DBS was effective in improving tremor, equivocal results were observed in those with ataxia.
Conclusions
DBS of select targets may represent an effective therapeutic strategy for uncommon tremor disorders, although the level of evidence is currently in its incipient form and based on single cases or limited case series. An international registry is, therefore, warranted to clarify selection criteria, long-term results, and optimal surgical targets.
Similar content being viewed by others
Avoid common mistakes on your manuscript.
Introduction
Tremor, defined as an involuntary, rhythmic, oscillatory movement of a body part [1] is a key semeiological feature of Parkinson disease (PD) and essential tremor (ET) [2, 3], as well as the cardinal symptom of less common but equally disabling movement disorders, namely Holmes tremor (HT), orthostatic tremor (OT), and fragile X-associated tremor/ataxia syndrome (FXTAS) [1, 4]. In addition, tremor represents a secondary yet disabling feature of immune-mediated neurological disorders such as multiple sclerosis (MS) and demyelinating peripheral neuropathies [1].
Tremulous disorders are classified basing on two axes, consisting of (a) the clinical and semeiological characteristics of tremor and (b) the underlying etiology [1]. HT is a rest, postural, and intention low-frequency (< 5 Hz) tremor [1] usually associated with an ischemic or demyelinating lesion of the cerebello-thalamo-cortical or dentate-rubro-olivary pathways, with superimposed nigrostriatal dysfunction [1, 5, 6]. OT is a 13–18 Hz tremor affecting the weight-bearing limbs and resulting in a sensation of unsteadiness and imbalance when standing [1, 4, 7]. Although the exact location of its generator remains unclear, available evidence suggests the involvement of the cerebellum and pons [7, 8]. MS-associated tremor is a heterogeneous syndromic entity that includes at least three different subtypes of tremor [1, 4]: a 4–5 Hz cerebellar tremor predominantly involving the upper extremities; a 3–5 Hz ataxic tremor of the head (“head titubation”) and the trunk; and a 7–12 Hz mild-amplitude postural hand tremor [9]. Neuropathy-associated tremor is a posture and intention 3–6 Hz tremor predominantly involving the upper limbs [1, 10], and possibly associated with an altered peripheral sensory input, which might prevent the cerebellum ability to correct limb position and velocity during voluntary movements [11, 12]. Finally, FXTAS-associated tremor is a posture and intention tremor associated with ataxia, parkinsonism, cognitive decline, peripheral neuropathy, autonomic dysfunction, and psychiatric disorders [13, 14], and caused by a trinucleotide repeat expansion in the premutation range (CGG block lengths 55–200) in the FMR1 gene.
While pharmacological therapies, mostly beta-blockers, benzodiazepines, and anticonvulsants represent the first line of treatment for common tremor disorders [15], uncommon tremors may be refractory to oral medications and, in selected cases, require advanced surgical treatments such as deep brain stimulation (DBS) [16, 17]. The risk/benefit profile of DBS in uncommon tremor disorders, however, remains to be clarified.
In this review, we sought to analyze the literature related to the safety and efficacy of DBS in uncommon tremor disorders, discussing clinical indications, anatomical targets, and programming strategies.
Materials and methods
We reviewed the literature for studies reporting the outcome of DBS in patients with HT, OT, MS-associated tremor, neuropathy-associated tremor, or FXTAS. Relevant articles were identified through electronic search of PubMed.gov and ClinicalTrials.gov using the following keywords: “tremor”, “Holmes tremor”, “orthostatic tremor”, “multiple sclerosis”, “multiple sclerosis tremor”, “neuropathy”, “neuropathic tremor”, “fragile X-associated tremor/ataxia syndrome”, and “fragile X.” No language restrictions were applied.
We selected studies involving humans. There were no restrictions applied to gender, age, disease duration, or disease severity. The data extracted included the following: (a) DBS targets including, but not limited to, ventral intermediate (Vim) nucleus, ventro-lateral (VL), ventralis oralis anterior (VOA) and ventralis oralis posterior (VOP) nuclei, posterior subthalamic area (PSA), subthalamic nucleus (STN), globus pallidus pars interna (GPi), and zona incerta (ZI); (b) magnitude of response, according to the available presentation of clinical data; (c) follow-up duration; (d) adverse events (AEs); and (e) stimulation settings.
Results
A total of 263 cases of uncommon tremor disorders treated with DBS were identified through a systematic review of PubMed.gov and ClinicalTrials.gov. Of these, 44 had Holmes tremor (HT); 18 had orthostatic tremor (OT); 177 had multiple sclerosis (MS)-associated tremor; 14 had neuropathy-associated tremor; and 10 had fragile X-associated tremor/ataxia syndrome (FXTAS).
Holmes tremor
We identified 24 studies (17 single case reports and 7 case series), which totaled 44 patients treated with DBS for HT (Table 1).
There were 31 patients treated with Vim-DBS: 13 received unilateral Vim-DBS, 5 bilateral Vim-DBS, and 13 Vim-DBS plus an additional target (GPi n = 5; STN n = 5; VOA/VOP border n = 3). Tremor improved in all cases, with a reduction ≥ 80% in 10/31 patients (32.3%). The extent of improvement was not specified in 12/31 patients (38.7%). The DBS electrode was removed in 1 patient treated with unilateral Vim-DBS due to lack of efficacy. Time to follow-up varied from 3 to 52 months. AEs were reported in 4/31 patients (12.9%), consisting in 1 infection of the implantable pulse generator (IPG), 1 case of facial paresthesia, 1 case of transient dysarthria, and 1 case of ataxia, paresthesia and dystonic movements. Stimulation frequency ranged from 100 to 180 Hz, intensity from 1.7 to 4.8 V, and pulse width from 60 to 210 μs (Table 1) [18,19,20,21,22,23,24,25,26,27,28,29,30,31,32,33,34,35,36,37].
GPi-DBS was used in 14 patients with HT: 7 received unilateral GPi-DBS, 2 bilateral GPi-DBS, and 5 GPi-DBS plus Vim-DBS. Tremor improved in all cases. A reduction ≥ 80% occurred in at least one component of tremor in 11/14 patients (78.6%). Follow-up spanned from 6 to 52 months. All but one study reported no occurrence of AEs, and 1 study did not report AEs. Stimulation frequency ranged from 130 to 185 Hz, intensity from 2.0 to 6.0 V, and pulse width from 90 to 210 μs (Table 1) [26, 30, 35,36,37].
STN-DBS was used in 6 patients with HT: 5 received unilateral STN-DBS plus Vim-DBS, and 1 STN-DBS plus Vo-DBS. Tremor improved in all cases, with a reduction ≥ 80% in 1/6 patients (16.7%). The follow-up duration ranged from 24 to 72 months. All but one study reported no occurrence of AEs, and one study did not report AEs. Stimulation frequency ranged from 135 to 145 Hz, intensity was 2.0 V, and pulse width varied from 90 to 210 μs (Table 1) [21, 34, 38].
Three cases were treated with ZI-DBS (1 bilateral ZI, 1 unilateral VOA/ZI, 1 unilateral lenticular fasciculus/ZI). Tremor improved in all cases, with a reduction ≥ 80% in 1/3 patients (33.4%). The follow-up duration ranged from 12 to 48 months. There was a lead infection 4 years after surgery, requiring removal of the system, and one case of transient dysphagia. Stimulation frequency ranged from 145 to 185 Hz, intensity from 1.8 to 3.0 V, and pulse width from 60 to 120 μs (Table 1) [39,40,41].
Orthostatic tremor
We identified 9 studies (6 single case reports and 3 case series), reporting a total of 18 patients treated with DBS for OT (Table 2).
Vim-DBS was used in 18 patients: 17 received bilateral Vim-DBS, and 1 unilateral Vim-DBS. Tremor amplitude reduction or increased latency to symptom onset after standing was reported in 15/18 patients (83.3%). One patient treated with bilateral Vim-DBS reported no improvement, and the patient receiving unilateral Vim-DBS reported only a temporary improvement, which lasted less than 6 months. Most of patients experienced a mild/moderate waning of tremor improvement over time. The follow-up duration ranged from 6 to 102 months. A total of 14 AEs was reported in 13/18 patients (72.2%), consisting in 1 skin infection over IPG, 2 surgical revisions due to cervical pain and lead dislocation, 1 generalized tonic–clonic seizure 3 days after surgery, 2 transient paresthesia, 2 gait ataxia, 1 unilateral foot dystonia, 1 case of dizziness, and 4 cases of speech difficulties. Stimulation frequency varied from 130 to 185 Hz, intensity from 1.5 to 4.0 V, and pulse width from 60 to 90 μs (Table 2) [42,43,44,45,46,47,48,49,50].
Multiple sclerosis-associated tremor
We identified 26 studies (3 single case reports, 22 case series, and 1 randomized clinical trial), for a total of 177 patients treated with DBS for MS-associated tremor (Table 3).
Vim-DBS was used in 146 patients: 93 received unilateral Vim-DBS, 26 bilateral Vim-DBS, 25 Vim-DBS plus an additional target (STN n = 11; VO n = 13; pre-lemniscal radiations n = 1), and 2 unspecified Vim laterality. Symptoms improved to some extent in 126/146 patients (83.6%). A transitory response was observed in 20/146 patients (13.7%). The follow-up duration ranged from 3 to 127 months. Several patients experienced AEs, encompassing MS exacerbation, seizures, intracerebral hematoma, gait/balance disturbance, asthenia and transient lower limb paresis, ataxia, dysarthria, paresthesias, and infections. Stimulation frequency ranged from 130 to 185 Hz, intensity from 0.5 to 8.0 V, and pulse width from 60 to 210 μs (Table 3) [25, 51,52,53,54,55,56,57,58,59,60,61,62,63,64,65,66,67,68,69,70].
ZI-DBS was used in 25 patients with MS-associated tremor: 4 received bilateral ZI-DBS, and 21 bilateral ZI-DBS plus VOP-DBS. Improvement of all the tremor components was reported for most of treated patients. Some cases gradually deteriorated across a follow-up of 12–62 months. AEs were reported in 8/25 patients (32%), consisting in 1 infection with scalp erosion leading to DBS removal, 2 other wound infections, 2 peri-operative seizure, 1 transient hemiparesis, 1 mild dysarthria, and 1 case of post-operative prolonged lethargy and reduced mobility. Stimulation frequency ranged from 40 to 105 Hz, intensity from 1.9 to 3.8 V, and pulse width from 90 to 330 μs (Table 3) [39, 71, 72].
VL thalamic DBS was used in six patients with MS-associated tremor: four received bilateral VL-DBS and 2 VL-DBS plus STN-DBS. Tremor improved in all cases, but follow-up was limited to fewer than 12 months. One study did not report AEs, and 1 study reported stimulation-induced paresthesia, dysarthria, and gait ataxia in a cohort of mixed patients, without specifying whether AEs occurred in MS patients. Stimulation frequency ranged from 130 to 145 Hz, intensity from 2.0 to 3.6 V, and pulse width was 60 μs in all cases (Table 3) [73, 74].
Neuropathy-associated tremor
We identified 9 studies (7 single case reports and 2 case series), reporting a total of 14 patients treated with DBS for tremor associated with neuropathy (Table 4).
Vim-DBS was used in 13 patients: 9 received bilateral Vim-DBS, and 4 unilateral Vim-DBS. Tremor improved in all cases. There was a complete resolution of tremor in 1/14 patient (7.1%), and a “marked” or “dramatic” tremor improvement in 2/14 patients (14.3%). Follow-up ranged from 6 months to 9 years. AEs were reported in 4/13 patients (30.8%), with 1 case of mild transient paresthesia, 1 case of dysarthria and worsening of gait ataxia, 1 case of mild dysarthria, and 1 skin erosion over IPG. Two studies reported no occurrence of AEs, and two studies did not report AEs. Stimulation frequency varied from 130 to 185 Hz, intensity from 0.6 to 4.5 V, and pulse width from 60 to 210 μs (Table 4) [12, 75,76,77,78,79,80,81].
One patient received unilateral PSA-DBS with a significant improvement of symptoms over a follow-up of 12 months. Intraoperative occurrence of visual phenomena, speech alterations, and paresthesia were reported. Stimulation frequency was 145 Hz, intensity 3.0 V, and pulse width 60 μs (Table 4) [82].
Fragile X-associated tremor/ataxia syndrome
We identified eight studies (seven case reports and one case series), reporting a total of ten patients treated with DBS for FXTAS (Table 5).
Vim-DBS was used in eight patients: four received bilateral Vim-DBS, two unilateral Vim-DBS, one bilateral Vim-DBS plus PSA-DBS, and one bilateral Vim-DBS plus bilateral STN-DBS. Tremor improved in all cases, with a reduction ≥ 50% in 5/8 patients (62.5%). In four patients, a concomitant improvement of ataxia was reported. The follow-up duration ranged from 6 to 60 months. AEs were assessed in all studies and reported in 5/8 patients (62.5%), consisting in three cases of ataxia and speech worsening (in one case with associated cognitive decline), and two cases of slight worsening of cognition after surgery. Two studies reported no occurrence of AEs. Stimulation frequency varied from 125 to 185 Hz, intensity from 1.5 to 5.4 V, and pulse width from 60 to 150 μs (Table 5) [83,84,85,86,87,88].
Vo/ZI-DBS was used in one patient with unquantified improvement of tremor and associated ataxia. Follow-up was 30 months, during which no AEs were reported. Stimulation settings were as follows: frequency = 176 Hz; intensity = 3.0 V (right) and 3.25 V (left); and pulse width = 90 μs (Table 5) [89].
PSA-DBS was used in one patient, resulting in a 58% improvement in tremor severity with no AEs occurrence. The follow-up duration was 8 months. Stimulation frequency was 160 Hz, intensity 2.8 V, and pulse width 120 μs (Table 5) [90].
Discussion
We reviewed and summarized studies that reported the outcomes of DBS in uncommon tremor disorders, namely HT, OT, MS-associated tremor, neuropathy-associated tremor, and FXTAS. Apart from one randomized clinical trial that tested the efficacy and safety of DBS in MS [70], the majority of studies consisted of single case reports or small case series. While this relevant limitation should be recognized, suggesting the possibility that a “file drawer effect” might have influenced our results, data reported in the literature seem to suggest that DBS may be clinically useful in uncommon tremor disorders.
The majority of cases received Vim-DBS, but other surgical targets were also tested, including GPi, ZI, PSA, VOA or VOP nuclei, STN, and VL thalamus (Fig. 1). A few patients with HT and MS-associated tremor received dual-target DBS, mostly Vim-DBS in association with GPi-DBS or STN-DBS. Available data do not permit one to draw final conclusions on the best target in each subtype of tremor. Nonetheless, promising results were observed with PSA-DBS and with dual-target DBS. In fact, the most conventional Vim-DBS target was sometimes confounded by worsening pre-existent ataxia in FXTAS, MS-, and neuropathy-associated tremor. Similar complications have been reported in patients with OT, where the accuracy of Vim-DBS targeting is complicated by the somatotopic arrangement of thalamic fibers. In fact, the thalamic region corresponding to the lower limbs is located laterally and is in close proximity to the internal capsule. Such specific anatomical organization accounts for the programming’s narrow therapeutic window that is frequently observed in uncommon tremor disorders. Motor and sensory stimulation-induced side effects consist of speech impairment, sensory issues, motor pulling, and possibly gait ataxia. New directional DBS systems capable of greater anatomical resolution may potentially address these difficulties, leading to an improvement in the risk/benefit profile of DBS treatment in uncommon tremor disorders.
Overall, our main findings can be summarized as follows:
Holmes tremor Vim-DBS, GPi-DBS, and STN-DBS appear to represent effective targets in HT, with a potential to modulate both cerebellar-thalamic and nigrostriatal outflows. However, given the multiple pathways involved in its pathogenesis, a combination of two targets might also be considered. In particular, positive results were observed in patients treated with Vim-DBS and GPi-DBS or with Vim-DBS and STN-DBS. The vast majority of studies reported a programming strategy based on single monopolar stimulation, with high frequency (160–180 Hz in most cases) and a pulse width of 60–90 μs (≥ 100 μs in few cases). Bipolar electrode configurations were occasionally used, mostly due to stimulation-induced side effects. Vim-DBS can be considered as a viable therapeutic option for HT patients that have failed multiple oral treatments, including levodopa, dopamine agonists, anticholinergics, and anticonvulsants [15, 91].
Orthostatic tremor Bilateral Vim-DBS demonstrated long-lasting efficacy in reducing tremor in most patients; a few cases treated with unilateral Vim-DBS reported transient and unsatisfactory results. The vast majority of studies reported a programming strategy based on single monopolar stimulation, with a frequency of 160–180 Hz (less frequently 130 Hz) and a pulse width of 60 or 90 μs. More complex programming strategies, such as bipolar configurations and interleaving, were occasionally used. Although partial efficacy in reducing OT has been demonstrated by benzodiazepines, followed by beta-blockers and anticonvulsants [7], the severity of OT symptoms usually progresses over time. This, therefore, lessens the efficacy of oral medications. Results from an international registry suggest that bilateral Vim-DBS might significantly improve the severity of symptoms in patients with incomplete response to oral medications.
Multiple sclerosis-associated tremor Dual-lead thalamic DBS (one targeting the VIM border and one targeting the ventralis oralis anterior-ventralis oralis posterior border) has the highest level of clinical trial support [70], providing a better control likely by stimulating the major pathways involved in MS-associated tremor, and cerebello-thalamo-cortical and pallidal pathways. Almost all studies reported the use of single monopolar stimulation, with a frequency ranging from 130 to 180 Hz and variable pulse width, ranging from 60 to 210 μs, but typically higher than other tremors. Interestingly, a very short frequency stimulation (40 Hz) was reported as efficacious in controlling the tremor of four patients. The application of DBS in MS-associated tremor is debated. Approximately 46% of MS patients have some form of tremor, severe enough to impair daily living activities in 5.8% of cases [9]. Beta-blockers and botulinum toxin injection [92, 93] should represent the first line of treatment. DBS can be considered in cases with particularly disabling symptoms, refractory to oral medications.
Neuropathy-associated tremor Vim-DBS appears to provide substantial improvement and improvement was reported in the only case treated with STN-DBS. The typical programming strategy was based on single monopolar stimulation, with a frequency of 130 or 180 Hz and a pulse width of 60 or 90 μs (in 3 cases > 100 μs). While the employment of DBS in neuropathy-associated tremor requires further confirmation by larger clinical trials, the significant impact played by tremor on functional activities in patients with immune-mediated neuropathies suggest that DBS might be a feasible therapeutic option for patients with neuropathy-associated tremor failing propranolol, primidone, and benzodiazepines [94].
Fragile X-associated tremor/ataxia syndrome Vim-DBS seems to be effective in improving tremor and sometimes also ataxia; however, a high rate of cases showed a worsening of ataxia, speech, and cognition after surgery, raising the question of the balance between the possible benefit and the potential harm deriving from DBS surgery in these patients. Most studies reported a stimulation frequency of 160–185 Hz and a pulse width of 90 μs or higher. Complex programming strategies such as bipolar or double monopolar stimulation were occasionally used, mostly due to stimulation-induced side effects. Further controlled clinical trials would help to clarify the extent of benefit achievable with Vim-DBS, as compared to oral medications, in patients with FXTAS.
Conclusions
Our review summarized the limited evidence available as well as some of the challenges associated with the use of DBS in uncommon tremor disorders. First, the inherent rarity of these conditions is, indeed, a limitation, which lends itself to certain publications being underpowered, and thus with an elevated risk of Type II errors. Second, the frequent association of uncommon tremor disorders with other movement disorders, such as ataxia, dystonia, and chorea, enhances the litany of confounders endemic to the analyses, which make disentanglement of cause-and-effect relationships challenging. Specifically, such clinical heterogeneity hampers the ability to determine the nature, and magnitude, of certain interventions and what outcomes they portend with great reliability. Third, the lack of validated scales for the objective measurements of disability and DBS-associated clinical benefits limits the generalizability of the results.
Given these limitations, particular efforts ought to be capturing the entirety of the patient’s clinical picture, including identification of co-existing movement disorders. Other variables to consider may include, but are not limited to, relevant genotyping, especially in syndromes that have been not well characterized, selection of DBS target(s), and ascertainment of optimal stimulation settings. Recent and future advances in DBS technology, such as directional stimulation, lead with more contacts, and adaptive stimulation stands to improve outcomes when using DBS for uncommon tremor disorders. An international registry to gather data from DBS-treated patients with uncommon tremor disorders is warranted to clarify selection criteria, long-term results, and optimal surgical targets.
References
Bhatia KP, Bain P, Bajaj N et al (2018) Consensus Statement on the classification of tremors. From the task force on tremor of the International Parkinson and Movement Disorder Society. Mov Disord 33:75–87. https://doi.org/10.1002/mds.27121
Tysnes OB, Storstein A (2017) Epidemiology of Parkinson’s disease. J Neural Transm (Vienna) 124:901–905. https://doi.org/10.1007/s00702-017-1686-y
Louis ED, Ferreira JJ (2010) How common is the most common adult movement disorder? Update on the worldwide prevalence of essential tremor. Mov Disord 25:534–541. https://doi.org/10.1002/mds.22838
Deuschl G, Bain P, Brin M (1998) Consensus statement of the Movement Disorder Society on Tremor. Ad Hoc Scientific Committee. Mov Disord 13(Suppl 3):2–23
Remy P, de Recondo A, Defer G et al (1995) Peduncular “rubral” tremor and dopaminergic denervation: a PET study. Neurology 45:472–477
Seidel S, Kasprian G, Leutmezer F, Prayer D, Auff E (2009) Disruption of nigrostriatal and cerebellothalamic pathways in dopamine responsive Holmes’ tremor. J Neurol Neurosurg Psychiatry 80:921–923. https://doi.org/10.1136/jnnp.2008.146324
Hassan A, Ahlskog JE, Matsumoto JY et al (2016) Orthostatic tremor: clinical, electrophysiologic, and treatment findings in 184 patients. Neurology 86:458–464. https://doi.org/10.1212/WNL.0000000000002328
Gallea C, Popa T, García-Lorenzo D et al (2016) Orthostatic tremor: a cerebellar pathology? Brain 139:2182–2197. https://doi.org/10.1093/brain/aww140
Rinker JR, Salter AR, Walker H et al (2015) Prevalence and characteristics of tremor in the NARCOMS multiple sclerosis registry: a cross-sectional survey. BMJ Open 5:e006714. https://doi.org/10.1136/bmjopen-2014-006714
Bain PG (2002) The management of tremor. J Neurol Neurosurg Psychiatry 72:I3–I9
Bain PG, Britton TC, Jenkins IH et al (1996) Tremor associated with benign IgM paraproteinaemic neuropathy. Brain 119:789–799
Weiss D, Govindan RB, Rilk A et al (2011) Central oscillators in a patient with neuropathic tremor: evidence from intraoperative local field potential recordings. Mov Disord 26:323–327. https://doi.org/10.1002/mds.23374
Hagerman RJ, Hagerman P (2016) Fragile X-associated tremor/ataxia syndrome—features, mechanisms and management. Nat Rev Neurol 12:403–412. https://doi.org/10.1038/nrneurol.2016.82
Hagerman RJ, Hall DA, Coffey S et al (2008) Treatment of fragile X-associated tremor ataxia syndrome (FXTAS) and related neurological problems. Clin Interv Aging 3:251–262
Puschmann A, Wszolek ZK (2011) Diagnosis and treatment of common forms of tremor. Semin Neurol 31:65–77. https://doi.org/10.1055/s-0031-1271312
Hyam JA, Pereira EAC, McCulloch P et al (2015) Implementing novel trial methods to evaluate surgery for essential tremor. Br J Neurosurg 29:334–339. https://doi.org/10.3109/02688697.2014.997670
Ramirez-Zamora A, Okun MS (2016) Deep brain stimulation for the treatment of uncommon tremor syndromes. Expert Rev Neurother 16:983–997. https://doi.org/10.1080/14737175.2016.1194756
Kudo M, Goto S, Nishikawa S et al (2001) Bilateral thalamic stimulation for Holmes’ tremor caused by unilateral brainstem lesion. Mov Disord 16:170–174
Goto S, Yamada K (2004) Combination of thalamic Vim stimulation and GPi pallidotomy synergistically abolishes Holmes’ tremor. J Neurol Neurosurg Psychiatry 75:1203–1204. https://doi.org/10.1136/jnnp.2003.023077
Pahwa R, Lyons KE, Kempf L, Wilkinson SB, Koller WC (2002) Thalamic stimulation for midbrain tremor after partial hemangioma resection. Mov Disord 17:404–407
Romanelli P, Brontë-Stewart H, Courtney T, Heit G (2003) Possible necessity for deep brain stimulation of both the ventralis intermedius and subthalamic nuclei to resolve Holmes tremor. Case report. J Neurosurg 99:566–571. https://doi.org/10.3171/jns.2003.99.3.0566
Samadani U, Umemura A, Jaggi JL et al (2003) Thalamic deep brain stimulation for disabling tremor after excision of a midbrain cavernous angioma. Case report. J Neurosurg 98:888–890. https://doi.org/10.3171/jns.2003.98.4.0888
Nikkhah G, Prokop T, Hellwig B, Lücking CH, Ostertag CB (2004) Deep brain stimulation of the nucleus ventralis intermedius for Holmes (rubral) tremor and associated dystonia caused by upper brainstem lesions. Report of two cases. J Neurosurg 100:1079–1083. https://doi.org/10.3171/jns.2004.100.6.1079
Piette T, Mescola P, Henriet M et al (2004) A surgical approach to Holmes’ tremor associated with high-frequency synchronous bursts. Rev Neurol (Paris) 160:707–711
Foote KD, Seignourel P, Fernandez HH et al (2006) Dual electrode thalamic deep brain stimulation for the treatment of posttraumatic and multiple sclerosis tremor. Neurosurgery 58:ONS-280–ONS-285 (discussion ONS-285–ONS-286)
Lim DA, Khandhar SM, Heath S et al (2007) Multiple target deep brain stimulation for multiple sclerosis related and poststroke Holmes’ tremor. Stereotact Funct Neurosurg 85:144–149. https://doi.org/10.1159/000099072
Diederich NJ, Verhagen Metman L, Bakay RA, Alesch F (2008) Ventral intermediate thalamic stimulation in complex tremor syndromes. Stereotact Funct Neurosurg 86:167–172. https://doi.org/10.1159/000120429
Peker S, Isik U, Akgun Y, Ozek M (2008) Deep brain stimulation for Holmes’ tremor related to a thalamic abscess. Childs Nerv Syst 24:1057–1062. https://doi.org/10.1007/s00381-008-0644-2
Acar G, Acar F, Bir LS, Kızılay Z, Cırak B (2010) Vim stimulation in Holmes’ tremor secondary to subarachnoid hemorrhage. Neurol Res 32:992–994. https://doi.org/10.1179/016164110X12714125204272
Aydin S, Abuzayed B, Kiziltan G et al (2013) Unilateral thalamic Vim and GPi stimulation for the treatment of Holmes’ tremor caused by midbrain cavernoma: case report and review of the literature. J Neurol Surg A Cent Eur Neurosurg 74:271–276. https://doi.org/10.1055/s-0032-1322549
Castrop F, Jochim A, Berends LP, Haslinger B (2013) Sustained suppression of holmes tremor after cessation of thalamic stimulation. Mov Disord 28:1456–1457. https://doi.org/10.1002/mds.25398
Issar NM, Hedera P, Phibbs FT, Konrad PE, Neimat JS (2013) Treating post-traumatic tremor with deep brain stimulation: report of five cases. Parkinsonism Relat Disord 19:1100–1105. https://doi.org/10.1016/j.parkreldis.2013.07.022
Follett MA, Torres-Russotto D, Follett KA (2014) Bilateral deep brain stimulation of the ventral intermediate nucleus of the thalamus for posttraumatic midbrain tremor. Neuromodulation 17:289–291. https://doi.org/10.1111/ner.12096
Kobayashi K, Katayama Y, Oshima H et al (2014) Multitarget, dual-electrode deep brain stimulation of the thalamus and subthalamic area for treatment of Holmes’ tremor. J Neurosurg 120:1025–1032. https://doi.org/10.3171/2014.1.JNS12392
Espinoza Martinez JA, Arango GJ, Fonoff ET et al (2015) Deep brain stimulation of the globus pallidus internus or ventralis intermedius nucleus of thalamus for Holmes tremor. Neurosurg Rev 38:753–763. https://doi.org/10.1007/s10143-015-0636-0
Kilbane C, Ramirez-Zamora A, Ryapolova-Webb E et al (2015) Pallidal stimulation for Holmes tremor: clinical outcomes and single-unit recordings in 4 cases. J Neurosurg 122:1306–1314. https://doi.org/10.3171/2015.2.JNS141098
Aydın S, Canaz H, Erdogan ET, Durmaz N, Topcular B (2017) Holmes’ tremor with shoulder pain treated by deep brain stimulation of unilateral ventral intermediate thalamic nucleus and globus pallidus internus. J Mov Disord 10:92–95. https://doi.org/10.14802/jmd.16051
Toda H, Nishida N, Iwasaki K (2017) Coaxial interleaved stimulation of the thalamus and subthalamus for treatment of Holmes tremor. Neurosurg Focus 42:V1. https://doi.org/10.3171/2017.4.FocusVid.16510
Plaha P, Khan S, Gill SS (2008) Bilateral stimulation of the caudal zona incerta nucleus for tremor control. J Neurol Neurosurg Psychiatry 79:504–513. https://doi.org/10.1136/jnnp.2006.112334
Bandt SK, Anderson D, Biller J (2008) Deep brain stimulation as an effective treatment option for post-midbrain infarction-related tremor as it presents with Benedikt syndrome. J Neurosurg 109:635–639. https://doi.org/10.3171/JNS/2008/109/10/0635
Grabska N, Rudzińska M, Dec-Ćwiek M et al (2014) Deep brain stimulation in the treatment of Holmes tremor—a long-term case observation. Neurol Neurochir Pol 48:292–295. https://doi.org/10.1016/j.pjnns.2014.06.002
Espay AJ, Duker AP, Chen R et al (2008) Deep brain stimulation of the ventral intermediate nucleus of the thalamus in medically refractory orthostatic tremor: preliminary observations. Mov Disord 23:2357–2362. https://doi.org/10.1002/mds.22271
Guridi J, Rodriguez-Oroz MC, Arbizu J et al (2008) Successful thalamic deep brain stimulation for orthostatic tremor. Mov Disord 23:1808–1811. https://doi.org/10.1002/mds.22001
Magariños-Ascone C, Ruiz FM, Millán AS et al (2010) Electrophysiological evaluation of thalamic DBS for orthostatic tremor. Mov Disord 25:2476–2477. https://doi.org/10.1002/mds.23333
Yaltho TC, Ondo WG (2011) Thalamic deep brain stimulation for orthostatic tremor. Tremor Other Hyperkinet Mov (N Y). https://doi.org/10.7916/D8NZ86C1
Lyons MK, Behbahani M, Boucher OK, Caviness JN, Evidente VG (2012) Orthostatic tremor responds to bilateral thalamic deep brain stimulation. Tremor Other Hyperkinet Mov (N Y). https://doi.org/10.7916/D8TQ608K
Contarino MF, Bour LJ, Schuurman PR et al (2015) Thalamic deep brain stimulation for orthostatic tremor: clinical and neurophysiological correlates. Parkinsonism Relat Disord 21:1005–1007. https://doi.org/10.1016/j.parkreldis.2015.06.008
Coleman RR, Starr PA, Katz M et al (2016) Bilateral ventral intermediate nucleus thalamic deep brain stimulation in orthostatic tremor. Stereotact Funct Neurosurg 94:69–74. https://doi.org/10.1159/000444127
Lehn AC, O’Gorman C, Olson S, Salari M (2017) Thalamic ventral intermediate nucleus deep brain stimulation for orthostatic tremor. Tremor Other Hyperkinet Mov (N Y) 7:479. https://doi.org/10.7916/D8280JHR
Merola A, Fasano A, Hassan A et al (2017) Thalamic deep brain stimulation for orthostatic tremor: a multicenter international registry. Mov Disord 32:1240–1244. https://doi.org/10.1002/mds.27082
Nguyen JP, Degos JD (1993) Thalamic stimulation and proximal tremor. A specific target in the nucleus ventrointermedius thalami. Arch Neurol 50:498–500
Siegfried J, Lippitz B (1994) Chronic electrical stimulation of the VL-VPL complex and of the pallidum in the treatment of movement disorders: personal experience since 1982. Stereotact Funct Neurosurg 62:71–75. https://doi.org/10.1159/000098599
Benabid AL, Pollak P, Gao D et al (1996) Chronic electrical stimulation of the ventralis intermedius nucleus of the thalamus as a treatment of movement disorders. J Neurosurg 84:203–214. https://doi.org/10.3171/jns.1996.84.2.0203
Geny C, Nguyen J-P, Pollin B et al (1996) Improvement of severe postural cerebellar tremor in multiple sclerosis by chronic thalamic stimulation. Mov Disord 11:489–494. https://doi.org/10.1002/mds.870110503
Montgomery EB, Baker KB, Kinkel RP, Barnett G (1999) Chronic thalamic stimulation for the tremor of multiple sclerosis. Neurology 53:625–628
Schulder M, Sernas T, Mahalick D, Adler R, Cook S (1999) Thalamic stimulation in patients with multiple sclerosis. Stereotact Funct Neurosurg 72:196–201. https://doi.org/10.1159/000029726
Taha JM, Janszen MA, Favre J (1999) Thalamic deep brain stimulation for the treatment of head, voice, and bilateral limb tremor. J Neurosurg 91:68–72. https://doi.org/10.3171/jns.1999.91.1.0068
Krauss JK, Simpson RK, Ondo WG et al (2001) Concepts and methods in chronic thalamic stimulation for treatment of tremor: technique and application. Neurosurgery 48:535–541 (discussion 541–543)
Hooper J, Taylor R, Pentland B, Whittle IR (2002) A prospective study of thalamic deep brain stimulation for the treatment of movement disorders in multiple sclerosis. Br J Neurosurg 16:102–109
Berk C, Carr J, Sinden M, Martzke J, Honey CR (2002) Thalamic deep brain stimulation for the treatment of tremor due to multiple sclerosis: a prospective study of tremor and quality of life. J Neurosurg 97:815–820. https://doi.org/10.3171/jns.2002.97.4.0815
Herzog J, Hamel W, Wenzelburger R et al (2007) Kinematic analysis of thalamic versus subthalamic neurostimulation in postural and intention tremor. Brain 130:1608–1625. https://doi.org/10.1093/brain/awm077
Schuurman PR, Bosch DA, Merkus MP, Speelman JD (2008) Long-term follow-up of thalamic stimulation versus thalamotomy for tremor suppression. Mov Disord 23:1146–1153. https://doi.org/10.1002/mds.22059
Moore GRW, Vitali AM, Leung E et al (2009) Thalamic stimulation in multiple sclerosis: evidence for a “demyelinative thalamotomy”. Mult Scler 15:1311–1321. https://doi.org/10.1177/1352458509345914
Mandat T, Koziara H, Tutaj M et al (2010) Thalamic deep brain stimulation for tremor among multiple sclerosis patients. Neurol Neurochir Pol 44:542–545. https://doi.org/10.1016/S0028-3843(14)60150-X
Torres CV, Moro E, Lopez-Rios A-L et al (2010) Deep brain stimulation of the ventral intermediate nucleus of the thalamus for tremor in patients with multiple sclerosis. Neurosurgery 67:646–651. https://doi.org/10.1227/01.NEU.0000375506.18902.3E
Hassan A, Ahlskog JE, Rodriguez M, Matsumoto JY (2012) Surgical therapy for multiple sclerosis tremor: a 12-year follow-up study. Eur J Neurol 19:764–768. https://doi.org/10.1111/j.1468-1331.2011.03626.x
Hosseini H, Mandat T, Waubant E et al (2012) Unilateral thalamic deep brain stimulation for disabling kinetic tremor in multiple sclerosis. Neurosurgery 70:66–69. https://doi.org/10.1227/NEU.0b013e31822da55c
Zakaria R, Vajramani G, Westmoreland L et al (2013) Tremor reduction and quality of life after deep brain stimulation for multiple sclerosis-associated tremor. Acta Neurochir (Wien) 155:2359–2364. https://doi.org/10.1007/s00701-013-1848-0
Mehanna R, Machado AG, Oravivattanakul S, Genc G, Cooper SE (2014) Comparing two deep brain stimulation leads to one in refractory tremor. Cerebellum 13:425–432. https://doi.org/10.1007/s12311-014-0552-9
Oliveria SF, Rodriguez RL, Bowers D et al (2017) Safety and efficacy of dual-lead thalamic deep brain stimulation for patients with treatment-refractory multiple sclerosis tremor: a single-centre, randomised, single-blind, pilot trial. Lancet Neurol 16:691–700. https://doi.org/10.1016/S1474-4422(17)30166-7
Nandi D, Aziz TZ (2004) Deep brain stimulation in the management of neuropathic pain and multiple sclerosis tremor. J Clin Neurophysiol 21:31–39
Thevathasan W, Schweder P, Joint C et al (2011) Permanent tremor reduction during thalamic stimulation in multiple sclerosis. J Neurol Neurosurg Psychiatry 82:419–422. https://doi.org/10.1136/jnnp.2010.213900
Whittle IR, Yau YH, Hooper J (2004) Mesodiencephalic targeting of stimulating electrodes in patients with tremor caused by multiple sclerosis. J Neurol Neurosurg Psychiatry 75:1210
Hamel W, Herzog J, Kopper F et al (2007) Deep brain stimulation in the subthalamic area is more effective than nucleus ventralis intermedius stimulation for bilateral intention tremor. Acta Neurochir (Wien) 149:749–758. https://doi.org/10.1007/s00701-007-1230-1
Růzicka E, Jech R, Zárubová K, Roth J, Urgosík D (2003) VIM thalamic stimulation for tremor in a patient with IgM paraproteinaemic demyelinating neuropathy. Mov Disord 18:1192–1195. https://doi.org/10.1002/mds.10510
Bayreuther C, Delmont E, Borg M, Fontaine D (2009) Deep brain stimulation of the ventral intermediate thalamic nucleus for severe tremor in anti-MAG neuropathy. Mov Disord 24:2157–2158. https://doi.org/10.1002/mds.22604
Breit S, Wächter T, Schöls L et al (2009) Effective thalamic deep brain stimulation for neuropathic tremor in a patient with severe demyelinating neuropathy. J Neurol Neurosurg Psychiatry 80:235–236. https://doi.org/10.1136/jnnp.2008.145656
McMaster J, Gibson G, Castro-Prado F, Vitali A, Honey CR (2009) Neurosurgical treatment of tremor in anti-myelin-associated glycoprotein neuropathy. Neurology 73:1707–1708. https://doi.org/10.1212/WNL.0b013e3181c1de66
Shields DC, Flaherty AW, Eskandar EN, Williams ZM (2011) Ventral intermediate thalamic stimulation for monoclonal gammopathy-associated tremor: case report. Neurosurgery 68:E1464–E1467. https://doi.org/10.1227/NEU.0b013e3182124633
Patel N, Ondo W, Jimenez-Shahed J (2014) Habituation and rebound to thalamic deep brain stimulation in long-term management of tremor associated with demyelinating neuropathy. Int J Neurosci 124:919–925. https://doi.org/10.3109/00207454.2014.895345
Cabañes-Martínez L, Álamo Del, de Pedro M, de Blas Beorlegui G, Bailly-Bailliere IR (2017) Long-term effective thalamic deep brain stimulation for neuropathic tremor in two patients with Charcot–Marie–Tooth disease. Stereotact Funct Neurosurg 95:102–106. https://doi.org/10.1159/000457963
Blomstedt P, Fytagoridis A, Tisch S (2009) Deep brain stimulation of the posterior subthalamic area in the treatment of tremor. Acta Neurochir (Wien) 151:31–36. https://doi.org/10.1007/s00701-008-0163-7
Ferrara JM, Adam OR, Ondo WG (2009) Treatment of fragile-X-associated tremor/ataxia syndrome with deep brain stimulation. Mov Disord 24:149–151. https://doi.org/10.1002/mds.22354
Senova S, Jarraya B, Iwamuro H et al (2012) Unilateral thalamic stimulation safely improved fragile X-associated tremor ataxia: a case report. Mov Disord 27:797–799. https://doi.org/10.1002/mds.24923
Xie T, Goodman R, Browner N et al (2012) Treatment of fragile X-associated tremor/ataxia syndrome with unilateral deep brain stimulation. Mov Disord 27:799–800. https://doi.org/10.1002/mds.24958
Mehanna R, Itin I (2014) Which approach is better: bilateral versus unilateral thalamic deep brain stimulation in patients with fragile X-associated tremor ataxia syndrome. Cerebellum 13:222–225. https://doi.org/10.1007/s12311-013-0530-7
Weiss D, Mielke C, Wächter T et al (2015) Long-term outcome of deep brain stimulation in fragile X-associated tremor/ataxia syndrome. Parkinsonism Relat Disord 21:310–313. https://doi.org/10.1016/j.parkreldis.2014.12.015
Tamás G, Kovács N, Varga NÁ et al (2016) Deep brain stimulation or thalamotomy in fragile X-associated tremor/ataxia syndrome? Case report. Neurol Neurochir Pol 50:303–308. https://doi.org/10.1016/j.pjnns.2016.04.004
dos Santos Ghilardi MG, Cury RG, dos Ângelos JS et al (2015) Long-term improvement of tremor and ataxia after bilateral DBS of VoP/zona incerta in FXTAS. Neurology 84:1904–1906. https://doi.org/10.1212/WNL.0000000000001553
Oyama G, Umemura A, Shimo Y et al (2014) Posterior subthalamic area deep brain stimulation for fragile X-associated tremor/ataxia syndrome. Neuromodulation 17:721–723. https://doi.org/10.1111/ner.12150
di Biase L, Munhoz RP (2016) Deep brain stimulation for the treatment of hyperkinetic movement disorders. Expert Rev Neurother 16:1067–1078. https://doi.org/10.1080/14737175.2016.1196139
Koch M, Mostert J, Heersema D, De Keyser J (2007) Tremor in multiple sclerosis. J Neurol 254:133–145. https://doi.org/10.1007/s00415-006-0296-7
Van Der Walt A, Sung S, Spelman T et al (2012) A double-blind, randomized, controlled study of botulinum toxin type A in MS-related tremor. Neurology 79:92–99. https://doi.org/10.1212/WNL.0b013e31825dcdd9
Charles PD, Esper GJ, Davis TL, Maciunas RJ, Robertson D (1999) Classification of tremor and update on treatment. Am Fam Physician 59:1565–1572
Acknowledgements
The authors are thankful to Dr. Alberto J. Espay for his intellectual contribution in the critical revision of the manuscript.
Author information
Authors and Affiliations
Contributions
CAA: study conception, data analysis, and writing the first draft; AF: data collection and analysis, abd manuscript revision; AR: data collection and analysis, and manuscript revision; LM: data collection and analysis, and manuscript revision; RB: data collection and analysis, and manuscript revision; LLS: revision of the manuscript for important intellectual contents; MZ: revision of the manuscript for important intellectual contents; APD: revision of the manuscript for important intellectual contents; GTM: revision of the manuscript for important intellectual contents; LL: revision of the manuscript for important intellectual contents; AM: study conception, data analysis, and writing and revision of the first draft. All the co-authors listed above gave their final approval of this manuscript version.
Corresponding author
Ethics declarations
Conflicts of interest
Dr. Artusi reports no conflict of interest; Dr. Farooqi reports no conflict of interest; Dr. Romagnolo has received grant support and speaker’s honoraria from AbbVie, speaker honoraria from Chiesi Farmaceutici and travel grants from Lusofarmaco and UCB Pharma; Dr. Marsili reports no conflict of interest; Dr. Balestrino reports no conflict of interest; Dr. Sokol reports no conflict of interest; Dr. Madybur is supported by the Mayfield Education research fund grant; he received honoraria from Medtronic and Boston Scientific; Dr. Wang has no disclosures; Dr. Zibetti has received speaker’s honoraria from Medtronic, Lundbeck, UCB Pharma, and AbbVie; Dr. Duker reports no conflict of interest; Dr. Lopiano has received honoraria for lecturing and travel grants from Medtronic, UCB Pharma, and AbbVie; Dr Merola is supported by NIH (KL2 TR001426) and has received speaker honoraria from CSL Behring, Cynapsus Therapeutics, and AbbVie. He has received grant support from Lundbeck and Abbott.
Rights and permissions
About this article
Cite this article
Artusi, C.A., Farooqi, A., Romagnolo, A. et al. Deep brain stimulation in uncommon tremor disorders: indications, targets, and programming. J Neurol 265, 2473–2493 (2018). https://doi.org/10.1007/s00415-018-8823-x
Received:
Revised:
Accepted:
Published:
Issue Date:
DOI: https://doi.org/10.1007/s00415-018-8823-x